



This list of clinical research protocols relating to genitourinary cancers is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER.

CLINICAL RESEARCH PROTOCOLS FOR GENITOURINARY CANCERS

Testicular Cancer

Phase III

FRE-FNCLCC-T93BP, EU-96016, FRE-T93BP Phase III Randomized Study of Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin (BEP) in Good-Prognosis Advanced Germ Cell Cancer

Chairperson: Pierre Kerbrat. Telephone: 33-2-9925-3280 (Rennes, France). Lead organization: Federation Nationale des Centres de Lutte Contre le Cancer. Age range: 15 to 70.

FRE-IT94, NCI-F94-0019, FRE-FNCLCC-IT94 Phase III Randomized Study of Salvage Therapy With PEI (CDDP/VP-16/IFF) or VeIP (VBL/IFF/CDDP) Alone or Followed by High-Dose CarboPEC (CBDCA/VP-16/CTX) and ABMT/PBSC Rescue for Germ Cell Tumors in Relapse or First Partial Remission

Chairperson: Jose-Louis Pico. Telephone: 33-1-4211-4239 (Villejeuf, France). Lead organization: Federation Nationale des Centres de Lutte Contre le Cancer. Age range: 16 and over.

EORTC-30983 Phase II/III Randomized Study of Bleomycin/Cisplatin/Etoposide (BEP) Versus Bleomycin/Cisplatin/Etoposide/Paclitaxel (T-BEP) in Men With Intermediate Prognosis Germ Cell Cancer

Chairperson: Ronald De Wit. Telephone: 31-10-439-1752 (The Netherlands). Lead organization:

EORTC Genito-Urinary Tract Cancer Cooperative Group. Age range: 16 to 50.

EORTC-30974 Phase III Randomized Study of Standard Cisplatin, Etoposide, and Ifosfamide (VIP) Followed By Sequential High Dose VIP and Stem Cell Rescue Versus Bleomycin, Etoposide, and Cisplatin (BEP) in Chemotherapy-Naive Men With Poor Prognosis Germ Cell Cancer

Chairperson: Gedske Daugaard. Telephone: 299-3545-4677 (Denmark). Lead organization: EORTC Genito-Urinary Tract Cancer Cooperative Group. Age range: 16 to 50.

MRC-TE19, EU-97003, EORTC-30982 Phase III Randomized Study of Adjuvant Radiotherapy versus a Single Cycle of Carboplatin in the Treatment of Stage I Testicular Seminoma

Chairperson: R.T. Oliver. Telephone: 44-171-601-8522 (United Kingdom). Lead organization: United Kingdom Medical Research Council. Age range: not specified.

MSKCC-94076, NCI-T94-0086D, E-3894 Phase III Randomized Study of BEP (BLEO/VP-16/CDDP) Alone vs BEP Followed by High-Dose CBDCA/VP-16/CTX With Hematopoietic Rescue in Males With Previously Untreated Poor and Intermediate Risk Germ Cell Tumors

Chairperson: Robert J. Motzer. Telephone: 212-639-6667. Lead organization: Memorial Sloan-Ket-

tering Cancer Center. Age range: at least 12.

Renal Cell Cancer

Phase III

NCI-91-C-0094B, NCI-T91-0053N Phase III Randomized Study of Intravenous Low-Dose vs Intravenous High-Dose vs Subcutaneous IL-2 for Metastatic Renal Cell Carcinoma

Chairperson: James Chung-Yin Yang. Telephone: 301-496-1574. Lead organization: Division of Clinical Sciences. Age range: 18 and over.

CWG-LU-8520, NCI-V97-1351 Phase III Randomized Study of Adjuvant High Dose Interleukin-2 in Patients With High Risk Stage III or IV Renal Cell Carcinoma

Chairperson: Joseph I. Clark. Telephone: 708-327-3236. Lead organization: Cytokine Working Group. Age range: 16 and over.

EORTC-30904, MRC-RE02 Phase III Randomized Study of Radical vs Kidney Sparing Surgery for Patients With Resectable Renal Cell Cancer

Chairperson: Hein van Poppel. Telephone: 32-016-34-6687 (Belgium). Lead organization: EORTC Genito-Urinary Tract Cancer Cooperative Group. Age range: any age.

EORTC-30951 Phase III Randomized Study of Interferon Alfa With vs Without Isotretinoin in

Patients With Metastatic Renal Cell Cancer

Chairperson: Nina Aass. Telephone: 47-2293-4000 (Norway). Lead organization: EORTC Genito-Urinary Tract Cancer Cooperative Group. Age range: 18 to 75.

Prostate Cancer

High Priority

VA-CSP-407, NCI-T94-01310, PIVOT-1, CLB-9492 NCI HIGH PRIORITY CLINICAL TRIAL — Phase III Randomized Study of Prostatectomy vs Expectant Observation With Palliative Therapy for Stage I/II Prostate Cancer (PIVOT)

Chairperson: Timothy James Wilt. Telephone: 612-725-2000, ext 2681. Lead organization: Veterans Affairs Cooperative Studies Program Coordinating Center - Perry Point. Age range: 75 and under.

Early Detection

MSKCC-98014, NCI-G98-1445 Phase III Randomized Study of the Effect of a Diet Low in Fat and High in Soy, Fruits, Vegetables, Green Tea, Vitamin E, and Fiber on PSA Levels in Patients With Prostate Cancer

Chairperson: Moshe Shike. Telephone: 212-639-7230. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

PLCO-1, NCI-P93-0050 A 16-Year Randomized Screening Study

for Prostate, Lung, Colorectal, and Ovarian Cancer - PLCO Trial

Chairperson: John K. Gohagan. Telephone: 301-496-8544. Lead organization: Early Detection Branch. Age range: 55 to 74.

Prevention

NCI-98-C-0099B Phase I Randomized Study of Genistein for Prevention of Cancer in Patients With No History of Cancer or With Asymptomatic Early Prostate Cancer or Other Malignancy

Chairperson: Chris H. Takimoto. Telephone: 301-496-0901. Lead organization: Division of Clinical Sciences. Age range: 18 and over.

Legend for Abbreviations:

CLB	=	Cancer & Leukemia Group B
CWG	=	Cytokine Working Group
E	=	Eastern Cooperative Oncology Group
EORTC	=	European Organization for Research on Treatment of Cancer
EU	=	European Voluntary Protocol
FRE	=	French Protocol
MRC	=	UK Medical Research Council
MSKCC	=	Memorial Sloan-Kettering Cancer Center
NCI	=	National Cancer Institute
PIVOT	=	Prostate Cancer Intervention vs Observation Trial
PLCO	=	NCI Prostate, Lung, Colorectal & Ovarian Cancer Screening Trial
VA-CSP	=	VA Cooperative Studies Program